Our Targeted Conditioning Agent
JSP191 is a targeted CD117 monoclonal antibody conditioning agent designed to enable safer and more effective curative hematopoietic stem cell transplants and stem cell gene therapies.
Our initial indication is severe combined immunodeficiency (SCID) for which we are currently conducting a Phase 1/2 study. We also are evaluating JSP191 in a Phase 1 study in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia. Jasper has partnered with academia as well as industry to expand the application of JSP191 to Fanconi anemia with Stanford University, sickle cell disease and chronic granulomatous disease with the NIH and gene therapies with Graphite Bio as well as Aruvant Sciences. Later this year, Jasper plans to initiate a pilot study to evaluate JSP191 in autoimmune diseases, including severe scleroderma, systemic lupus erythematosus and multiple sclerosis.